On a mission to help patients regain vision, LambdaVision (NSF-1632465) develops a protein-based artificial retina for people with retinal degenerative diseases. The artificial retina mimics the light-absorbing properties of human photoreceptors, replacing the function of these damaged cells in the retinas of blind patients. LambdaVision recently secured over $17 million in funding and launched nine missions to the International Space Station. Article via Pulse 2.0